<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">medsovet</journal-id><journal-title-group><journal-title xml:lang="ru">Медицинский Совет</journal-title><trans-title-group xml:lang="en"><trans-title>Meditsinskiy sovet = Medical Council</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2079-701X</issn><issn pub-type="epub">2658-5790</issn><publisher><publisher-name>REMEDIUM GROUP Ltd.</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.21518/2079-701X-2016-13-61-65</article-id><article-id custom-type="elpub" pub-id-type="custom">medsovet-1363</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>Дислипидемия</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>Dyslipidemia</subject></subj-group></article-categories><title-group><article-title>«Парадокс холестерина» у пациентов с хронической сердечной недостаточностью. Современное состояние проблемы</article-title><trans-title-group xml:lang="en"><trans-title>CHOLESTEROL PARADOX IN PATIENTS WITH CHRONIC CARDIAC INSUFFICIENCY MODERN STATE OF THE PROBLEM</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>ШЕПЕЛЬ</surname><given-names>Р. Н.</given-names></name><name name-style="western" xml:lang="en"><surname>SHEPEL</surname><given-names>R. N.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Москва</p></bio><bio xml:lang="en"><p>Moscow</p></bio><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Государственный научно-исследовательский центр профилактической медицины Минздрава России</institution><country>Россия</country></aff><aff xml:lang="en"><institution>State Scientific and Research Center of Preventive Medicine of the Ministry of Health of Russia</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2016</year></pub-date><pub-date pub-type="epub"><day>30</day><month>12</month><year>2016</year></pub-date><volume>0</volume><issue>13</issue><fpage>61</fpage><lpage>65</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; ШЕПЕЛЬ Р.Н., 2016</copyright-statement><copyright-year>2016</copyright-year><copyright-holder xml:lang="ru">ШЕПЕЛЬ Р.Н.</copyright-holder><copyright-holder xml:lang="en">SHEPEL R.N.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.med-sovet.pro/jour/article/view/1363">https://www.med-sovet.pro/jour/article/view/1363</self-uri><abstract><p>Хроническая сердечная недостаточность (ХСН) – распространенное заболевание среди населения Российской Федерации и, как правило, связана с наличием ишемической болезни сердца (ИБС). Гиперхолестеринемия является основным фактором риска развития ИБС, но, как это ни парадоксально, у пациентов с ХСН часто определяется низкий уровень холестерина, что, в свою очередь, связано с плохим прогнозом. Уменьшение уровня холестерина статинами снижает заболеваемость и смертность у пациентов с ИБС, не имеющих ХСН, и, возможно, также улучшает прогноз у больных с ХСН. Однако результаты ряда исследований свидетельствуют о том, что высокий уровень холестерина у пациентов с ХСН ассоциируется с лучшими показателями выживаемости. В данной статье рассматривается «парадокс холестерина» у пациентов с ХСН, возможные его механизмы и современные алгоритмы ведения указанной группы больных.</p></abstract><trans-abstract xml:lang="en"><p>Chronic cardiac insufficiency (CCI) is a wide-spread disease among the population of the Russian Federation and, as a rule, it is related to presence of the ischemic heart disease (IHD). Hypercholesterinemia is the major risk factor of IHD development but, however paradoxical it might seem, IHD patients often present a low cholesterol level, which, in its turn, is associated with the bad forecast. Reduction of the cholesterol level by statins reduces the incidence and mortality rate in IHD patients without CCI and possible improves the forecast in patients with CCI. But results of a number of studies testify that the high cholesterol level in patients with CCI is associated with better survival rates. This article provides data on the cholesterol paradox in CCI patients, its possible mechanisms and modern algorithms of the above-stated patients group management.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>холестерин</kwd><kwd>хроническая сердечная недостаточность</kwd><kwd>«парадокс холестерина»</kwd><kwd>розувастатин</kwd></kwd-group><kwd-group xml:lang="en"><kwd>cholesterol</kwd><kwd>chronic cardiac insufficiency</kwd><kwd>cholesterol paradox</kwd><kwd>rosuvastatin</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Pekkanen J, Linn S, Heiss G et al. Ten-year mortality from cardiovascular disease in relation to cholesterol level among men with and without preexisting cardiovascular disease. N Engl J Med, 1990, 322: 1700-1707.</mixed-citation><mixed-citation xml:lang="en">Pekkanen J, Linn S, Heiss G et al. Ten-year mortality from cardiovascular disease in relation to cholesterol level among men with and without preexisting cardiovascular disease. N Engl J Med, 1990, 322: 1700-1707.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Kannel WB, Belanger AJ. Epidemiology of heart failure. Am Heart J, 1991, 121: 951-957.</mixed-citation><mixed-citation xml:lang="en">Kannel WB, Belanger AJ. Epidemiology of heart failure. Am Heart J, 1991, 121: 951-957.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Kjekshus J, Pedersen TR, Olsson AG, Faergeman O, Pyorala K. The effects of simvastatin on the incidence of heart failure in patients with coronary heart disease. J Card Fail, 1997, 3: 249-254.</mixed-citation><mixed-citation xml:lang="en">Kjekshus J, Pedersen TR, Olsson AG, Faergeman O, Pyorala K. The effects of simvastatin on the incidence of heart failure in patients with coronary heart disease. J Card Fail, 1997, 3: 249-254.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Vredevoe DL, Woo MA, Doering LV et al. Skin test anergy in advanced heart failure secondary to either ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol, 1998, 82(3): 323-328.</mixed-citation><mixed-citation xml:lang="en">Vredevoe DL, Woo MA, Doering LV et al. Skin test anergy in advanced heart failure secondary to either ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol, 1998, 82(3): 323-328.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Richartz BM, Radovancevic B, Frazier OH et al. Low serum cholesterol levels predict high perioperative mortality in patients supported by a left-ventricular assist system. Cardiology, 1998, 89(3): 184-188.</mixed-citation><mixed-citation xml:lang="en">Richartz BM, Radovancevic B, Frazier OH et al. Low serum cholesterol levels predict high perioperative mortality in patients supported by a left-ventricular assist system. Cardiology, 1998, 89(3): 184-188.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Rauchhaus M, Koloczek V, Volk H et al. Inflammatory cytokines and the possible immunological role for lipoproteins in chronic heart failure. Int J Cardiol, 2000, 76(2–3): 125-33.</mixed-citation><mixed-citation xml:lang="en">Rauchhaus M, Koloczek V, Volk H et al. Inflammatory cytokines and the possible immunological role for lipoproteins in chronic heart failure. Int J Cardiol, 2000, 76(2–3): 125-33.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Rauchhaus M, Clark AL, Doehner W et al. The relationship between cholesterol and survival in patients with chronic heart failure. J Am Coll Cardiol, 2003, 2(11): 1933-1940.</mixed-citation><mixed-citation xml:lang="en">Rauchhaus M, Clark AL, Doehner W et al. The relationship between cholesterol and survival in patients with chronic heart failure. J Am Coll Cardiol, 2003, 2(11): 1933-1940.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Afsarmanesh N, Horwich TB, Fonarow GC. Total cholesterol levels and mortality risk in nonischemic systolic heart failure. Am Heart J, 2006, 152(6): 1077-1083.</mixed-citation><mixed-citation xml:lang="en">Afsarmanesh N, Horwich TB, Fonarow GC. Total cholesterol levels and mortality risk in nonischemic systolic heart failure. Am Heart J, 2006, 152(6): 1077-1083.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">May HT, Muhlestein JB, Carlquist JF et al. Relation of serum total cholesterol, C-reactive protein levels, and statin therapy to survival in heart failure. Am J Cardiol, 2006, 98: 653- 658.</mixed-citation><mixed-citation xml:lang="en">May HT, Muhlestein JB, Carlquist JF et al. Relation of serum total cholesterol, C-reactive protein levels, and statin therapy to survival in heart failure. Am J Cardiol, 2006, 98: 653- 658.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Greene SJ, Vaduganathan M, Lupi L et al. Prog nostic significance of serum total cholesterol and triglyceride levels in patients hospitalized for heart failure with reduced ejection fraction (from the EVEREST Trial). Am J Cardiol, 2013, 111(4): 574-81.</mixed-citation><mixed-citation xml:lang="en">Greene SJ, Vaduganathan M, Lupi L et al. Prog nostic significance of serum total cholesterol and triglyceride levels in patients hospitalized for heart failure with reduced ejection fraction (from the EVEREST Trial). Am J Cardiol, 2013, 111(4): 574-81.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Freitas HF, Barbosa EA, Rosa FH et al. Association of HDL cholesterol and triglycerides with mortality in patients with heart failure. Braz J Med Biol Res, 2009, 42(5): 420-405.</mixed-citation><mixed-citation xml:lang="en">Freitas HF, Barbosa EA, Rosa FH et al. Association of HDL cholesterol and triglycerides with mortality in patients with heart failure. Braz J Med Biol Res, 2009, 42(5): 420-405.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Horwich TB, Hernandez AZ et al. Cholesterol levels and in-hospital mortality in patients with acute decompensated heart failure. Am Heart J, 2008, 156(6): 1170-1076.</mixed-citation><mixed-citation xml:lang="en">Horwich TB, Hernandez AZ et al. Cholesterol levels and in-hospital mortality in patients with acute decompensated heart failure. Am Heart J, 2008, 156(6): 1170-1076.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Myasoedova E, Crowson CS, Kremers HM, et al. Lipid paradox in rheumatoid arthritis: the impact of serum lipid measures and systemic inflammation on the risk of cardiovascular disease. Ann Rheum Dis, 2011, 70: 482-487.</mixed-citation><mixed-citation xml:lang="en">Myasoedova E, Crowson CS, Kremers HM, et al. Lipid paradox in rheumatoid arthritis: the impact of serum lipid measures and systemic inflammation on the risk of cardiovascular disease. Ann Rheum Dis, 2011, 70: 482-487.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Yoon CH, Youn TJ, Ahn S et al. Korean Heart Failure Registry. Low serum total cholesterol level is a surrogate marker, but not a risk factor, for poor outcome in patients hospitalized with acute heart failure: a report from the Korean Heart Failure Registry. J Card Fail, 2012, 18(3): 194-201.</mixed-citation><mixed-citation xml:lang="en">Yoon CH, Youn TJ, Ahn S et al. Korean Heart Failure Registry. Low serum total cholesterol level is a surrogate marker, but not a risk factor, for poor outcome in patients hospitalized with acute heart failure: a report from the Korean Heart Failure Registry. J Card Fail, 2012, 18(3): 194-201.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Volpato S, Leveille SG, Corti MC et al. The value of serum albumin and high-density lipoprotein cholesterol in defining mortality risk in older persons with low serum cholesterol. J Am Geriatr Soc, 2001, 49: 1142-1147.</mixed-citation><mixed-citation xml:lang="en">Volpato S, Leveille SG, Corti MC et al. The value of serum albumin and high-density lipoprotein cholesterol in defining mortality risk in older persons with low serum cholesterol. J Am Geriatr Soc, 2001, 49: 1142-1147.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Volpato S, Zuliani G, Guralnik JM et al. The inverse association between age and cholesterol level among older patients: The role of poor health status. Gerontology, 2001, 47: 36-45.</mixed-citation><mixed-citation xml:lang="en">Volpato S, Zuliani G, Guralnik JM et al. The inverse association between age and cholesterol level among older patients: The role of poor health status. Gerontology, 2001, 47: 36-45.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Krumholz HM, Seeman TE, Merrill SS et al. Lack of association between cholesterol and coronary heart diseaёse mortality and morbidity and all-cause mortality in persons older than 70 years. JAMA, 1994, 272: 1335-1340.</mixed-citation><mixed-citation xml:lang="en">Krumholz HM, Seeman TE, Merrill SS et al. Lack of association between cholesterol and coronary heart diseaёse mortality and morbidity and all-cause mortality in persons older than 70 years. JAMA, 1994, 272: 1335-1340.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Bonilla-Palomas JL, Gámez-López AL, Moreno- Conde M et al. Total cholesterol levels predict inhospital mortality in patients with acute heart failure aged 70 years or older. Rev Esp Geriatr Gerontol, 2016, 13. pii: S0211-139X(15)00238-3.</mixed-citation><mixed-citation xml:lang="en">Bonilla-Palomas JL, Gámez-López AL, Moreno- Conde M et al. Total cholesterol levels predict inhospital mortality in patients with acute heart failure aged 70 years or older. Rev Esp Geriatr Gerontol, 2016, 13. pii: S0211-139X(15)00238-3.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Wierzbicki AS, Poston R, Ferro A. The lipid and non-lipid effects of statins. Pharmacol Ther, 2003, 99(1): 95-112.</mixed-citation><mixed-citation xml:lang="en">Wierzbicki AS, Poston R, Ferro A. The lipid and non-lipid effects of statins. Pharmacol Ther, 2003, 99(1): 95-112.</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet, 1994, 344 (8934): 1383-1389.</mixed-citation><mixed-citation xml:lang="en">Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet, 1994, 344 (8934): 1383-1389.</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Shepherd J, Cobbe SM, Ford I et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med, 1995, 333(20): 1301-1307.</mixed-citation><mixed-citation xml:lang="en">Shepherd J, Cobbe SM, Ford I et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med, 1995, 333(20): 1301-1307.</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. N Engl J Med, 1998, 339(19): 1349-1357.</mixed-citation><mixed-citation xml:lang="en">Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. N Engl J Med, 1998, 339(19): 1349-1357.</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Anker SD, Chua TP, Swan JW. Hormonal changes and catabolic/anabolic imbalance in chronic heart failure. The importance for cardiac cachexia. Circulation, 1997, 96: 526-534.</mixed-citation><mixed-citation xml:lang="en">Anker SD, Chua TP, Swan JW. Hormonal changes and catabolic/anabolic imbalance in chronic heart failure. The importance for cardiac cachexia. Circulation, 1997, 96: 526-534.</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Pasini E, Aquilani R, Gheorghiade M et al. Malnutrition, muscle wasting and cachexia in chronic heart failure: The nutritional approach. Ital Heart J, 2003, 4: 232-235.</mixed-citation><mixed-citation xml:lang="en">Pasini E, Aquilani R, Gheorghiade M et al. Malnutrition, muscle wasting and cachexia in chronic heart failure: The nutritional approach. Ital Heart J, 2003, 4: 232-235.</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Anker SD, Ponikowski P, Varney S et al. Wasting as independent risk factor for mortality in chronic heart failure. Lancet, 1997, 349: 1050-1053.</mixed-citation><mixed-citation xml:lang="en">Anker SD, Ponikowski P, Varney S et al. Wasting as independent risk factor for mortality in chronic heart failure. Lancet, 1997, 349: 1050-1053.</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Witte KK, Clark AL. Nutritional abnormalities contributing to cachexia in chronic illness. Int J Cardiol, 2002, 85: 23-31.</mixed-citation><mixed-citation xml:lang="en">Witte KK, Clark AL. Nutritional abnormalities contributing to cachexia in chronic illness. Int J Cardiol, 2002, 85: 23-31.</mixed-citation></citation-alternatives></ref><ref id="cit27"><label>27</label><citation-alternatives><mixed-citation xml:lang="ru">Anker SD, Coats AJ. Cardiac cachexia: A syndrome with impaired survival and immune and neuroendocrine activation. Chest, 1999, 115: 836-847.</mixed-citation><mixed-citation xml:lang="en">Anker SD, Coats AJ. Cardiac cachexia: A syndrome with impaired survival and immune and neuroendocrine activation. Chest, 1999, 115: 836-847.</mixed-citation></citation-alternatives></ref><ref id="cit28"><label>28</label><citation-alternatives><mixed-citation xml:lang="ru">Anker SD, Chua TP, Ponikowski P et al. Hormonal changes and catabolic/anabolic imbalance in chronic heart failure and their importance for cardiac cachexia. Circulation, 1997, 96: 526-534.</mixed-citation><mixed-citation xml:lang="en">Anker SD, Chua TP, Ponikowski P et al. Hormonal changes and catabolic/anabolic imbalance in chronic heart failure and their importance for cardiac cachexia. Circulation, 1997, 96: 526-534.</mixed-citation></citation-alternatives></ref><ref id="cit29"><label>29</label><citation-alternatives><mixed-citation xml:lang="ru">Rauchhaus M, Clark AL, Doehner W et al. The relationship between cholesterol and survival in patients with chronic heart failure. J Am Coll Cardiol, 2003, 42: 1933-1940.</mixed-citation><mixed-citation xml:lang="en">Rauchhaus M, Clark AL, Doehner W et al. The relationship between cholesterol and survival in patients with chronic heart failure. J Am Coll Cardiol, 2003, 42: 1933-1940.</mixed-citation></citation-alternatives></ref><ref id="cit30"><label>30</label><citation-alternatives><mixed-citation xml:lang="ru">Mortensen SA, Leth A, Agner E, Rohde M. Doserelated decrease of serum coenzyme Q10 during treatment with HMG-CoA reductase inhibitors. Mol Aspects Med, 1997, 18(Suppl): S137-S144.</mixed-citation><mixed-citation xml:lang="en">Mortensen SA, Leth A, Agner E, Rohde M. Doserelated decrease of serum coenzyme Q10 during treatment with HMG-CoA reductase inhibitors. Mol Aspects Med, 1997, 18(Suppl): S137-S144.</mixed-citation></citation-alternatives></ref><ref id="cit31"><label>31</label><citation-alternatives><mixed-citation xml:lang="ru">Moosmann B, Behl C. Selenoprotein synthesis and side-effects of statins. Lancet, 2004, 363(9412): 892-894.</mixed-citation><mixed-citation xml:lang="en">Moosmann B, Behl C. Selenoprotein synthesis and side-effects of statins. Lancet, 2004, 363(9412): 892-894.</mixed-citation></citation-alternatives></ref><ref id="cit32"><label>32</label><citation-alternatives><mixed-citation xml:lang="ru">Драпкина О.М., Шепель Р.Н. Статины и риск развития инфекционных заболеваний. Рациональная фармакотерапия в кардиологии, 2013, 9(3): 306-310./ Drapkina O.M., Shepel R.N. Statins and risk of infectious diseases development. Ratsionalnaya farmakoterapia v kardiologii, 2013, 9 (3): 306-310.</mixed-citation><mixed-citation xml:lang="en">Драпкина О.М., Шепель Р.Н. Статины и риск развития инфекционных заболеваний. Рациональная фармакотерапия в кардиологии, 2013, 9(3): 306-310./ Drapkina O.M., Shepel R.N. Statins and risk of infectious diseases development. Ratsionalnaya farmakoterapia v kardiologii, 2013, 9 (3): 306-310.</mixed-citation></citation-alternatives></ref><ref id="cit33"><label>33</label><citation-alternatives><mixed-citation xml:lang="ru">Kjekshus J, Dunselman P, Blideskog M et al. A statin in the treatment of heart failure, Controlled rosuvastatin multinational study in heart failure (CORONA): study design and baseline characteristics. Eur J Heart Fail, 2005, 7: 1059-69.</mixed-citation><mixed-citation xml:lang="en">Kjekshus J, Dunselman P, Blideskog M et al. A statin in the treatment of heart failure, Controlled rosuvastatin multinational study in heart failure (CORONA): study design and baseline characteristics. Eur J Heart Fail, 2005, 7: 1059-69.</mixed-citation></citation-alternatives></ref><ref id="cit34"><label>34</label><citation-alternatives><mixed-citation xml:lang="ru">GISSIР-HF Investigators. Effect of rosuvastatin in patients with chronic heart failure (the GISSIРHF trial): a randomized, doubleР blind, placeboРcontrolled trial. Lancet, 2008, 372: 1231-1239.</mixed-citation><mixed-citation xml:lang="en">GISSIР-HF Investigators. Effect of rosuvastatin in patients with chronic heart failure (the GISSIРHF trial): a randomized, doubleР blind, placeboРcontrolled trial. Lancet, 2008, 372: 1231-1239.</mixed-citation></citation-alternatives></ref><ref id="cit35"><label>35</label><citation-alternatives><mixed-citation xml:lang="ru">Национальные рекомендации ОССН, РКО и РНМОТ по диагностике и лечению ХСН (четвертый пересмотр). Журнал Сердечная Недостаточность, 2013, 81(7): 379-472./ National Recommendations of Cardiovascular Insufficiency Expert Association, Russian Cardiologic Society and Russian Scientific Medical Therapist Society on diagnostics and therapy of CCI (Revision Four). Serdechnaya Nedostatochnost Journal, 2013, 81 (7): 379- 472.</mixed-citation><mixed-citation xml:lang="en">Национальные рекомендации ОССН, РКО и РНМОТ по диагностике и лечению ХСН (четвертый пересмотр). Журнал Сердечная Недостаточность, 2013, 81(7): 379-472./ National Recommendations of Cardiovascular Insufficiency Expert Association, Russian Cardiologic Society and Russian Scientific Medical Therapist Society on diagnostics and therapy of CCI (Revision Four). Serdechnaya Nedostatochnost Journal, 2013, 81 (7): 379- 472.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
